Journal
ONCOLOGIST
Volume 23, Issue 6, Pages 647-649Publisher
WILEY
DOI: 10.1634/theoncologist.2017-0591
Keywords
-
Categories
Ask authors/readers for more resources
This Commentary addresses the FDA approval of pembrolizumab and the changes necessary in clinical practice to identify patients who would benefit from such treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
